There should be a PR from this said last Tuesday!!
Post# of 325
Posted On: 09/14/2015 3:58:31 PM
There should be a PR from this said last Tuesday!!!
"TAMPA, Fla., Sept. 9, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.
Oxis Biotech Chairman and CEO Anthony J Cataldo is scheduled to present to investors on Thursday September 10, 2015 at 3:45pm. Mr. Cataldo will present details of Oxis' latest licensing agreement for DT2219ARL. DT2219ARL targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
"We are very excited to update the investment community on the exciting developments at Oxis. DT2219ARL has the potential to be important and significant cancer drug," said Anthony J. Cataldo, Chairman and CEO of Oxis Biotech.
At the conference there will be opportunities for investors to meet one on one with Mr. Cataldo. Mr. Cataldo will be meeting with institutional investors and analysts throughout the week in New York. Investors interested in meeting with Mr. Cataldo should contact investor relations at the number provided below.
About Oxis Biotech, Inc.
Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com."
"TAMPA, Fla., Sept. 9, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.
Oxis Biotech Chairman and CEO Anthony J Cataldo is scheduled to present to investors on Thursday September 10, 2015 at 3:45pm. Mr. Cataldo will present details of Oxis' latest licensing agreement for DT2219ARL. DT2219ARL targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
"We are very excited to update the investment community on the exciting developments at Oxis. DT2219ARL has the potential to be important and significant cancer drug," said Anthony J. Cataldo, Chairman and CEO of Oxis Biotech.
At the conference there will be opportunities for investors to meet one on one with Mr. Cataldo. Mr. Cataldo will be meeting with institutional investors and analysts throughout the week in New York. Investors interested in meeting with Mr. Cataldo should contact investor relations at the number provided below.
About Oxis Biotech, Inc.
Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, DT2219ARL is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. DT2219ARL simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When DT2219ARL binds to cancer cells, the cancer cells internalize DT2219ARL and are killed due to the action of drug's cytotoxic payload. DT2219ARL has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com."
(1)
(0)GT Biopharma Inc. (OXISD) Stock Research Links
Scroll down for more posts ▼